Why Your Body Fights Every Diet
身体为什么总在阻止你变瘦
Fat was never the enemy. It is the body's oldest insurance policy: surplus calories packaged into triglyceride droplets inside fat cells, drawn down when food runs out. The episode follows one causal chain from that original purpose to the modern disease cluster: what fat is, why the body hoards it, why it starts leaking into the wrong organs, how the food industry and history built the environment that overflowed the warehouse, why weight loss fights back, and what actually works in the real world. The through-line is that fatty liver, insulin resistance, and carotid plaque are not separate diseases — they are one story about fat stored in the wrong place, at the wrong scale, in a body that is still defending its reserves on purpose. The ending reinterprets the opening: the problem was never that you are storing fat; it is that an engineered environment made the storage catastrophic, and whoever holds the tools — individual, medical, or regulatory — changes the outcome.
脂肪从来不是敌人,它是身体最古老的保险:把多余热量打包成甘油三酯存进脂肪细胞,等没东西吃时再取出来。影片顺着一条因果链讲到底:脂肪到底是什么,身体为什么囤它,它为什么开始漏到不该去的地方,食品工业和历史如何造出了把仓库撑爆的环境,减脂为什么会被身体反击,以及现实中到底什么有用。主线是:脂肪肝、胰岛素抵抗、颈动脉斑块不是三种病,而是同一个故事——脂肪存错了地方、存过了量,而身体还在刻意死守储备。结尾重释开场:问题从来不是你存了脂肪,而是被设计过的环境让储存变成灾难;谁拿到工具——个体、医学、还是监管——结果就不同。
Fifty-eight kilograms, gone in seven months. That was the average result for the fourteen contestants of The Biggest Loser, season eight. On finale night, the numbers on the scale made the whole room cry. Six years later, the same people lay in a metabolic chamber, breathing through a mask, while researchers measured how many calories they burned at rest. They were burning, on average, about five hundred calories a day less than the formula for their age, height, and weight predicts. The show was over. Most of the weight had come back. Their bodies were still keeping the books from the year they were starved.
- ·
Fifty-eight kilograms, seven months
Fifty-eight kilograms, gone in seven months. That was the average result for the fourteen contestants of The Biggest Loser, season eight. On finale night, the numbers on the scale made the whole room cry. Six years later, the same people lay in a metabolic chamber, breathing through a mask, while researchers measured how many calories they burned at rest. They were burning, on average, about five hundred calories a day less than the formula for their age, height, and weight predicts. The show was over. Most of the weight had come back. Their bodies were still keeping the books from the year they were starved.
Selected opening: number and time first, then the lab reversal, then the question the whole episode answers.
- ·
Danny Cahill, one body
Danny Cahill taped a photo to his refrigerator. In it he weighed 195 kilograms, standing on the scale of The Biggest Loser. Seven months later he was 87 kilograms and had won the season. In the six-year follow-up he lay in a metabolic chamber again. His body was burning about 800 fewer calories a day than a man his age and size should. He won the competition. His body was still defending the man who had starved.
Person-in-trouble opening: one extreme case instead of the group average, personal stakes first.
- ·
One scale, two readings
The same scale, two readings. In 2009 the finale showed fourteen people had lost an average of fifty-eight kilograms each. Six years later, the same people had regained an average of forty-one. Between the two readings sat a number nobody filmed: their resting metabolism, about five hundred calories a day below what their bodies should burn. The cameras caught people getting thin and getting heavy again. They missed the ledger that never recovered.
Time-cut opening: the unphotographed data becomes the subject of the film.
- 01
Why does the body keep fighting years after a diet ends?
In seven months, fourteen contestants on The Biggest Loser lost an average of 58 kilograms. Six years later, even after most of the weight had returned, their resting metabolism was still about 500 calories a day below what their age, height, and weight predict. The show's famine was over; the accounting was not. The number comes from one extreme show and has been debated, but it names a real puzzle.
Fothergill et al. 2016 — persistent metabolic adaptation: https://pubmed.ncbi.nlm.nih.gov/27136388/
If a calorie deficit is simple physics, why does the body get a vote?
- 02
If a calorie deficit is simple physics, why does the body get a vote?
Energy balance is real, but neither side is measurable. Food labels can be off by 20 percent; absorption varies between people, gut bacteria, and processing; and the body quietly lowers resting metabolism, temperature, and spontaneous movement when intake drops. The arithmetic is real. The math is fake.
Hall et al. 2011 — energy imbalance quantification: https://pubmed.ncbi.nlm.nih.gov/21872751/; FDA nutrition-label rounding/tolerance: https://www.fda.gov/food/nutrition-facts-label/how-understand-and-use-nutrition-facts-label
What exactly does the body change when hunger starts?
- 03
What exactly does the body change when hunger starts?
The daily budget is mostly background: resting organs about 60 percent, digestion about 10 percent, NEAT the rest, deliberate exercise the smallest line. Kevin Hall's model: each kilogram lost cuts expenditure about 25 kcal a day and raises appetite about 95–100 kcal a day. In 1944, 36 men in Minnesota ate about 1,500 kcal a day for six months, lost a quarter of their weight, hoarded recipes, felt cold in summer, and several overate past their starting weight when food returned.
Hall et al. 2011; Levine 2006 — NEAT: https://pubmed.ncbi.nlm.nih.gov/16439708/; Minnesota experiment: https://renfrewcenter.com/the-minnesota-semi-starvation-experiment-what-it-teaches-us-about-eating-disorders/
Who tells the body to save energy?
- 04
Who tells the body to save energy?
Fat cells make leptin, and in 1994 the gene missing in an obese mouse strain was found. Injecting it made mice slim, and headlines wrote the cure. In people it barely worked, because obese people have more leptin (about 31 vs 7.5 in lean people) and the brain has gone numb to it. In humans, leptin resistance is four lines of inference (high serum, weak exogenous response, lower CSF-to-serum ratio, animal evidence); weight loss drops leptin faster than fat, and the brain overreacts to the drop. One hormone, two failure modes.
Zhang et al. 1994: https://www.nature.com/articles/372425a0; Considine 1996: https://pubmed.ncbi.nlm.nih.gov/8593770/; Schwartz 1996: https://pubmed.ncbi.nlm.nih.gov/8614834/; Heymsfield 1999: https://jamanetwork.com/journals/jama/fullarticle/191909; Rosenbaum 2005: https://pubmed.ncbi.nlm.nih.gov/16116137/
If fat is this loud, why does where it sits matter?
- 05
If fat is this loud, why does where it sits matter?
A fat cell is a triglyceride droplet that grows or multiplies but never retires; in adults about 10 percent of the cells are replaced each year. Subcutaneous fat is the safe warehouse. Visceral fat drains straight into the liver through the portal vein, so thin-outside-fat-inside people get sick while some heavier people stay metabolically healthy. Disease follows the spill, not the scale. Brown fat is real (50–100 g in adults, roughly 100 kcal a day when cold-activated) but a frontier, not a tool.
The Secret Life of Fat Cells: https://pmc.ncbi.nlm.nih.gov/articles/PMC6161053/; Björntorp portal theory: https://pubmed.ncbi.nlm.nih.gov/10945144/; Thomas TOFI: https://www.semanticscholar.org/paper/a6047e118b30073d5cb5fbb3cce31232738730ec; Spalding 2008: https://www.nature.com/articles/nature06902; Cypess 2009: https://www.nejm.org/doi/full/10.1056/NEJMoa0810780
Where does the spill land first?
- 06
Where does the spill land first?
The liver. Circulating fatty acids are the main source of liver fat; de novo lipogenesis from sugar is a real but limited amplifier, about a quarter of the fat in fatty-liver patients and only in a surplus state. Fructose's real damage is weak satiety and fast liquid calories. MASLD now affects about one in three adults, mostly silently, and in 2024 the first drug for advanced liver scarring was approved.
Donnelly 2005 — liver fat sources: https://pubmed.ncbi.nlm.nih.gov/15834806/; Teff 2004 — fructose and satiety hormones: https://pubmed.ncbi.nlm.nih.gov/15531646/; Geidl-Flueck & Gerber 2023: https://pubmed.ncbi.nlm.nih.gov/36753292/; MASLD burden: https://www.sciencedirect.com/science/article/abs/pii/S1043276024000365; FDA resmetirom 2024: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
Does the spill stop at the liver?
- 07
Does the spill stop at the liver?
No. The same leak reaches the blood-sugar system and the artery wall: LDL slips under a leaky artery lining, oxidizes, immune cells eat it, and their remains build plaque. Fatty liver, insulin resistance, and carotid plaque are one cause in three coats. In an equal calorie deficit, insulin does not decide who loses weight; it is a background regulator, and insulin resistance holds the brake on fat mobilization.
JACC lipid spillover: https://www.jacc.org/doi/full/10.1016/j.jacbts.2026.101532; carotid plaque biology: https://pubmed.ncbi.nlm.nih.gov/38673936/; insulin resistance and hyperinsulinemia: https://doi.org/10.1210/clinem/dgaa886
If the body defends fat this well, why did the whole world get fat at once?
- 08
If the body defends fat this well, why did the whole world get fat at once?
In 2022 more than a billion people lived with obesity and adult rates roughly doubled since 1990. Genes do not move that fast; the food environment did. Kevin Hall's inpatient trial matched diets for calories, sugar, fat, and protein, differing only in processing, and people ate about 500 extra kcal a day without noticing. The environment was engineered: 1960s sugar-industry-funded science, 1972 supersized fries, and a projected 4.32 trillion dollars a year in global cost by 2035.
NCD-RisC 2024: https://doi.org/10.1016/S0140-6736(23)02750-2; Hall 2019: https://doi.org/10.1016/j.cmet.2019.05.008; Kearns sugar industry: https://www.healio.com/news/cardiology/20161005/sugar-industry-sponsored-research-to-downplay-sugars-role-in-heart-disease; BBC supersizing: https://www.bbc.co.uk/programmes/b01k6l6l; World Obesity: https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity
So can a single person still win?
- 09
So can a single person still win?
Yes, with the defense understood. DIETFITS put 609 adults on healthy low-carb or low-fat diets for a year; the difference was 0.7 kg, so the label is not the lever. Protein (20–30 percent thermic effect), resistance training, and a modest deficit negotiate with the system. GLP-1 drugs work at the appetite source (STEP-1: about 15 kg / 15 percent) but cost muscle, rebound on withdrawal, and access stays unequal. Mexico's sugar-sweetened-beverage tax cut purchases about 6 percent in the first year and about 12 percent by year end, with the biggest response among low-income households. More than 10,000 people in the National Weight Control Registry have kept large losses for years. The ending returns to the fourteen: they did not fail; their bodies fought a war they did not know about, and now the individual, the doctor, and the state can fight it together.
Gardner DIETFITS 2018: https://pubmed.ncbi.nlm.nih.gov/29466592/; STEP-1: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183; STEP-4 withdrawal: https://www.nejm.org/doi/full/10.1056/NEJMoa2107388; Colchero 2016: https://www.bmj.com/content/352/bmj.h6704; NWCR: https://pubmed.ncbi.nlm.nih.gov/16002825/
- Opening pressure
The liver that never drank
Roughly 30 percent of adults worldwide now carry MASLD — fat in the liver without heavy alcohol use — and most never feel it until it shows up on a scan.
- Historical turn
The fat mouse that fooled the world
In 1994 Friedman identified the hormone missing from an obese mouse strain; the anticipated weight-loss pill turned out to be proof that fat is an endocrine organ defending its reserves.
- Historical turn
The year the world got fat together
Adult obesity roughly tripled between 1975 and 2022, to more than a billion people, with almost no country spared — genes did not change, the food environment did.
- Mechanism
The warehouse and its limits
Fat cells store triglyceride in a single droplet and can grow or multiply; when the subcutaneous depot reaches capacity, the surplus has to go somewhere else.
- Mechanism
The portal pipe
Visceral fat drains directly into the liver through the portal vein, and a high-fructose diet makes the liver convert surplus into new fat — the de novo lipogenesis behind MASLD.
- Conceptual reversal
Fat in the wrong zip code
Insulin resistance, fatty liver, and carotid plaque are one chain of ectopic fat — the disease is not obesity, it is fat stored where the body never designed storage.
- Conceptual reversal
The thin person with the sick fat
TOFI — thin outside, fat inside — shows normal-weight people with dangerous visceral fat; BMI hides the location that actually decides risk.
- Application decision
The maintenance recipe
DIETFITS found the label (low-fat versus low-carb) barely mattered; long-term maintainers eat at a deficit, exercise about an hour a day, and monitor themselves relentlessly.
- Application decision
The drug-and-surgery era
STEP-1 averaged 17.3 kg lost — larger than any diet trial — at the cost of muscle, rebound on stopping, and a price list that only recently dropped to $675 a month; metabolic surgery triples diabetes remission and cuts cardiovascular events.
- Countercase
The tax that moved a country
Mexico's 2014 sugar-sweetened-beverage tax cut purchases about 12 percent in year one, with the biggest response among low-income households — environment can be reversed.
- Frontier and return
Who holds the tools
A market projected near $200 billion, a liver disease renamed to admit it is metabolic, and a billion people caught between biology and an engineered food supply.
- Return and payoff
Insurance, not enemy
The liver full of fat was never a moral failure. It is an insurance system overwhelmed by an engineered environment — and the question is who holds the tools.
- Input
- Surplus dietary energy, subcutaneous fat-storage capacity, visceral fat mass, liver de novo lipogenesis, and an environment that keeps raising intake.
- Transformation
- Fat cells store triglyceride and secrete hormones; when the safe depot fills, fatty acids spill into visceral, hepatic, muscular, and perivascular tissue, where they drive insulin resistance, liver steatosis, and arterial inflammation while the body simultaneously defends its reserves by lowering metabolism and raising hunger.
- Output
- A defended weight plateau, a rising disease cluster (MASLD, insulin resistance, atherosclerosis), and — with the right tools — partial reversal of the leak.
- Limit
- The system is asymmetric: storage is cheap and defended, drainage is slow and incomplete, and every tool — diet, drug, or surgery — either leaks muscle, rebounds, or depends on access and price.
Adipose storage capacity
- Input
- Surplus dietary energy and the size of the subcutaneous depot.
- Transformation
- Fat cells take up triglyceride, grow (hypertrophy), and recruit new cells (hyperplasia) until the safe storage limit is reached.
- Output
- A limited-capacity warehouse that can absorb only so much surplus.
- Limit
- When capacity is exhausted, energy storage moves to organs never designed for it.
- Evidence
- NCBI — Adipose Tissue: Physiology to Metabolic Dysfunction: https://www.ncbi.nlm.nih.gov/books/NBK555602/
Fat as an endocrine organ
- Input
- Fat mass and energy balance.
- Transformation
- Adipose tissue secretes leptin (energy-storage signal), adiponectin (protective), and inflammatory cytokines.
- Output
- A hormonal report of stored energy that drives appetite and expenditure.
- Limit
- Leptin resistance and falling adiponectin disconnect the signal from the response.
- Evidence
- The Secret Life of Fat Cells: https://pmc.ncbi.nlm.nih.gov/articles/PMC6161053/
Portal drainage of visceral fat
- Input
- Visceral adipose tissue and its lipolytic outflow.
- Transformation
- Visceral fat drains free fatty acids directly into the liver through the portal vein, feeding hepatic lipogenesis and gluconeogenesis.
- Output
- A liver flooded with substrate it was not designed to process.
- Limit
- Portal theory explains one route; spillover from dysfunctional subcutaneous fat also contributes.
- Evidence
- Björntorp — metabolic difference between visceral and subcutaneous fat: https://pubmed.ncbi.nlm.nih.gov/10945144/
Hepatic de novo lipogenesis
- Input
- Fructose and surplus carbohydrate reaching the liver.
- Transformation
- The liver converts fructose preferentially into new triglycerides, outpacing glucose-driven synthesis.
- Output
- Liver fat accumulation — the MASLD pathway — without any alcohol.
- Limit
- DNL is one contributor among many; total energy surplus and adipose spillover matter as much.
- Evidence
- Geidl-Flueck & Gerber 2023 — fructose drives de novo lipogenesis: https://pubmed.ncbi.nlm.nih.gov/36753292/
Lipid spillover and lipotoxicity
- Input
- Ectopic fatty acids in muscle, pancreas, and perivascular tissue.
- Transformation
- Fatty-acid intermediates disrupt insulin signaling and provoke inflammation in organs with no storage capacity.
- Output
- Insulin resistance, beta-cell stress, and arterial-wall inflammation.
- Limit
- Not every fat person has spillover; storage location and adipose function decide individual risk.
- Evidence
- JACC 2026 — Rethinking obesity through the lens of lipid spillover: https://www.jacc.org/doi/full/10.1016/j.jacbts.2026.101532
Visceral and liver fat to carotid plaque
- Input
- Visceral adiposity, hepatic fat, and perivascular adipose tissue.
- Transformation
- Imaging cohorts show visceral and liver fat tracking with carotid intima-media thickness and plaque burden; perivascular fat adds local inflammatory signaling.
- Output
- Measurable atherosclerosis in people whose BMI may look normal.
- Limit
- Associations are strong and graded but not proof that removing fat alone reverses plaque.
- Evidence
- Communications Medicine 2025 — visceral and hepatic fat as determinants of carotid atherosclerosis: https://link.springer.com/article/10.1038/s43856-025-01123-y
TOFI — thin outside, fat inside
- Input
- Normal BMI with disproportionately high visceral fat.
- Transformation
- MRI phenotyping identifies a normal-weight subphenotype with ectopic fat and metabolic risk.
- Output
- Metabolic disease hidden behind a healthy-looking weight.
- Limit
- Location beats BMI; screening with waist or imaging, not weight alone, catches it.
- Evidence
- Thomas et al. 2012 — TOFI phenotype via MRI/MRS: https://www.semanticscholar.org/paper/The-Missing-Risk%3A-MRI-and-MRS-Phenotyping-of-and-Thomas-Parkinson/a6047e118b30073d5cb5fbb3cce31232738730ec
Dynamic energy balance
- Input
- A calorie deficit created by diet.
- Transformation
- Resting expenditure falls roughly 25 kcal per kilogram lost while appetite rises roughly 95 kcal per kilogram — the body adjusts both sides of the ledger.
- Output
- A plateau where the deficit quietly disappears.
- Limit
- Static rules such as 500 kcal cut per pound per week ignore adaptation and mispredict weight loss.
- Evidence
- Hall et al. 2011 — quantification of energy imbalance: https://pubmed.ncbi.nlm.nih.gov/21872751/
Metabolic adaptation
- Input
- Rapid, large weight loss.
- Transformation
- Resting metabolism stays suppressed beyond what body size predicts; Biggest Loser contestants burned ~500 kcal/day less than expected six years later.
- Output
- A long-term handicap against regain.
- Limit
- Slower loss and muscle preservation blunt adaptation but do not erase it.
- Evidence
- Fothergill et al. 2016 — persistent metabolic adaptation: https://pubmed.ncbi.nlm.nih.gov/27136388/
The engineered appetite
- Input
- Ultra-processed food matched for calories and macros.
- Transformation
- The same energy and nutrients, processed differently, drove roughly 508 kcal/day more intake in an inpatient trial.
- Output
- An environment that overfeeds the storage system from the intake side.
- Limit
- The mechanism is not fully pinned down — eating rate, texture, reward, and gut signals all change together.
- Evidence
- Hall et al. 2019 — ultra-processed diets: https://doi.org/10.1016/j.cmet.2019.05.008
GLP-1 pharmacology
- Input
- An incretin signal that normally rises after eating.
- Transformation
- Semaglutide mimics GLP-1, turning hunger down at its source; STEP-1 averaged 17.3 kg lost over 68 weeks.
- Output
- Weight loss larger than any diet trial.
- Limit
- A meaningful share of the loss is lean mass unless protein and training are added; weight returns on discontinuation; access is priced.
- Evidence
- STEP-1 (NEJM 2021): https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Metabolic surgery
- Input
- Bariatric procedures that restrict intake and change gut signaling.
- Transformation
- Surgery produces durable weight loss, roughly three times the diabetes-remission rate of medical therapy, and large reductions in macrovascular events.
- Output
- The most effective treatment for severe obesity and its metabolic consequences.
- Limit
- Operative and nutritional risk, cost, and access; results vary by procedure and patient.
- Evidence
- ACC journal scan — long-term outcomes of medical management versus bariatric surgery: https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2024/03/05/13/14/long-term-outcomes-of-medical
The insulin-glucose door
- Input
- Glucose entering the blood after a meal, plus insulin released by the pancreas.
- Transformation
- Insulin signals muscle and liver cells through an IRS1-PI3K-Akt chain; the GLUT4 transporter moves to the cell surface and imports glucose.
- Output
- Blood glucose returns to normal; surplus is stored as glycogen or fat.
- Limit
- Ectopic fat inside cells, especially diacylglycerol and ceramides, blocks IRS1 so GLUT4 never arrives and glucose stays high.
- Evidence
- GLUT4 and the IRS1/PI3K/Akt insulin pathway: https://www.sciencedirect.com/science/article/abs/pii/S1096719210005585; DAG-PKC and lipid-induced insulin resistance: https://pmc.ncbi.nlm.nih.gov/articles/PMC7547588/
Beta-cell burnout
- Input
- Years of high glucose and fat spilling into the pancreas.
- Transformation
- Glucotoxicity and lipotoxicity push beta cells to lose their identity and stop secreting insulin; Accili and colleagues showed the mechanism is dedifferentiation more than cell death.
- Output
- Insulin secretion falls, blood glucose climbs, and diabetes is diagnosed.
- Limit
- Some loss is reversible if caught early, but UKPDS traced the decline starting more than a decade before diagnosis, with about half of beta-cell function already gone by then.
- Evidence
- Accili et al. 2012 — Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure: https://doi.org/10.1016/j.cell.2012.07.029; UKPDS 16 — type 2 diabetes as a progressive disease: https://pubmed.ncbi.nlm.nih.gov/7621954/
Plaque anatomy
- Input
- LDL crossing a leaky artery lining into the wall.
- Transformation
- LDL oxidizes; macrophages swallow it and become foam cells; a fibrous cap forms around a lipid-rich necrotic core.
- Output
- A plaque that can grow silently, thin its cap, tear, and clot.
- Limit
- Heavy calcification marks stable plaques; the dangerous ones are soft and inflamed. ApoB tracks risk better than LDL-C.
- Evidence
- Cellular biology of atherosclerosis: https://pmc.ncbi.nlm.nih.gov/articles/PMC4395483/; Molecular pathways of vulnerable carotid plaques: https://pubmed.ncbi.nlm.nih.gov/38673936/
SignalWaist circumference, liver fat on imaging, fasting glucose and lipids, and rate of weight loss with hunger or muscle loss.
Decision ownerThe individual and clinician; the prescriber and payer for GLP-1 or surgery; the regulator for the food environment.
ThresholdWhether ectopic fat or metabolic risk crosses a clinical line; whether drug eligibility, cost, and coverage make the tool accessible; whether policy can move intake at population scale.
ActionChoose a modest deficit with protein and resistance training; prescribe GLP-1 or refer for metabolic surgery with muscle-protection protocols; tax or reformulate the products engineered to overfeed.
ConsequenceIndividual tools are undermined by metabolic defense and regain risk; medical tools move more weight but shift the cost to muscle, stopping, and price; environmental tools are the only ones that fight on the same side as the defense.
The maintenance recipe
SignalA person entering a calorie deficit; rate of loss, hunger, and muscle loss rising.
Decision ownerThe dieter and their clinician or coach.
ActionSet a modest deficit, a high protein target, and resistance training; slow the rate when adaptation shows up as hunger and fatigue.
ConsequenceDIETFITS found label adherence, not macronutrient choice, decided outcome; NWCR maintainers exercise about an hour a day and monitor themselves — the tools that protect muscle and slow loss are what change the odds.
The drug-and-surgery decision
SignalObesity with metabolic disease or repeated lifestyle failure.
Decision ownerThe clinician, payer, and patient.
ActionPrescribe GLP-1 with protein and resistance training; refer for metabolic surgery when severity warrants; plan for discontinuation and muscle protection.
ConsequenceSTEP-1-scale loss becomes possible but shifts the fight to muscle loss, rebound on stopping, and a price list — analysts see a market projected near $200 billion while access remains unequal.
The environment decision
SignalUltra-processed intake and sugar-sweetened beverages driving excess consumption.
Decision ownerRegulators and food manufacturers.
ActionTax or reformulate the products engineered to overfeed; make the healthy choice the default.
ConsequenceMexico's 2014 beverage tax cut purchases about 12 percent in year one, with the largest response among low-income households — the only lever that fights on the same side as the body's defense.
The spillover story is not a verdict. Subcutaneous storage can be healthy — metabolically benign obesity exists — and thin people can be sick: the TOFI phenotype (thin outside, fat inside) shows normal-weight adults with dangerous visceral fat, which is why location, not BMI alone, decides risk. The environment is also reversible: Mexico's soda tax moved consumption, and the National Weight Control Registry proves large losses can be maintained for decades with sustained behavior. And the medical tools have real boundaries — GLP-1 loses muscle and rebounds on withdrawal, surgery carries operative and nutritional risk, and neither is accessible to most of the billion people affected. Blaming willpower is wrong; declaring biological determinism is equally wrong; the evidence cuts both ways.
- NCD-RisC — Worldwide trends in underweight and obesity from 1990 to 2022 (Lancet 2024)
- World Obesity Federation — Prevalence of Obesity
- Friedman — Obesity not a personal failing, but a battle against biology (Rockefeller/Science)
- The Secret Life of Fat Cells (ACS Central Science / PMC)
- NCBI — Adipose Tissue: Physiology to Metabolic Dysfunction
- Björntorp — Metabolic difference between visceral fat and subcutaneous abdominal fat
- Khanna, Nerlekar & Bhat — Rethinking obesity through the lens of lipid spillover (JACC BTS 2026)
- 2023 multisociety Delphi consensus — new fatty liver disease nomenclature (MASLD)
- MASLD — current status and future trends of the global burden
- WGO — MASLD: time to dismantle the apocalypse narrative
- Communications Medicine 2025 — visceral and hepatic fat as determinants of carotid atherosclerosis
- Geidl-Flueck & Gerber 2023 — Fructose drives de novo lipogenesis affecting metabolic health
- Thomas et al. 2012 — The missing risk: MRI/MRS phenotyping of abdominal adiposity and ectopic fat (TOFI)
- Renfrew Center — The Minnesota Semi-Starvation Experiment
- Evolutionary perspectives on the obesity epidemic (PubMed review)
- Hall et al. 2019 — Ultra-processed diets cause excess calorie intake and weight gain
- The Atlantic — The Sugar Wars
- Healio — Sugar industry sponsored research to downplay sugar's role in heart disease (Kearns et al.)
- BBC — The Men Who Made Us Fat (supersizing history)
- JAMA — Food Politics, Obesity, and the 'Wicked Mess' We Are In
- Colchero et al. 2016 — Beverage purchases from stores in Mexico under the excise tax (BMJ)
- Hall et al. 2011 — Quantification of the effect of energy imbalance on bodyweight
- Fothergill et al. 2016 — Persistent metabolic adaptation six years after The Biggest Loser
- Levine 2006 — NEAT: the crouching tiger hidden dragon of societal weight gain
- Gardner et al. 2018 — DIETFITS randomized clinical trial
- Wing & Phelan — Long-term weight loss maintenance (National Weight Control Registry)
- STEP-1 trial — Semaglutide 2.4 mg in adults with overweight or obesity (NEJM 2021)
- STEP-4 trial — Continuation versus withdrawal of semaglutide (NEJM 2021)
- ACC journal scan — Long-term outcomes of medical management versus bariatric surgery
- Oseberg trial — Gastric bypass versus sleeve gastrectomy at 5 years (Lancet Diabetes & Endocrinology)
- Yang et al. 2023 — Long-term effect of bariatric/metabolic surgery versus pharmacologic therapy in T2DM (meta-analysis)
- J.P. Morgan — How supply and demand for weight-loss drugs is playing out
- Fierce Pharma — Novo to knock down Ozempic, Wegovy list prices
- WHO Western Pacific — Asian BMI thresholds for overweight and obesity
- ConscienHealth — The carbohydrate-insulin model versus energy balance model debate
- Talchai, Xuan, Lin, Sussel & Accili 2012 — Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure (Cell)
- Son & Accili 2023 — Reversing pancreatic beta-cell dedifferentiation (Exp Mol Med)
- UKPDS 16 — Overview of 6 years of therapy of type II diabetes: a progressive disease (Diabetes 1995)
- Splanchnic regulation of glucose production (PubMed review)
- Insulin resistance and hyperinsulinemia: the egg and the chicken (JCEM 2021)
- Recent insights into the cellular biology of atherosclerosis
- Molecular pathways of vulnerable carotid plaques at risk of ischemic stroke
- Degree of carotid plaque calcification in relation to symptomatic outcome
- FDA — Nutrition Facts label rounding and tolerance
- Zhang et al. 1994 — positional cloning of the mouse obese gene (Nature)
- Considine et al. 1996 — serum immunoreactive-leptin concentrations (NEJM)
- Schwartz et al. 1996 — cerebrospinal fluid leptin in obesity (Nat Med)
- Heymsfield et al. 1999 — recombinant leptin for weight loss (JAMA)
- Rosenbaum et al. 2005 — low-dose leptin reverses weight-loss energy expenditure (JCI)
- Spalding et al. 2008 — fat cell turnover in adults (Nature)
- Cypess et al. 2009 — brown adipose tissue in adult humans (NEJM)
- Donnelly et al. 2005 — sources of fatty acids stored in liver (JCI)
- Teff et al. 2004 — dietary fructose reduces circulating insulin and leptin (JCEM)
- FDA — first treatment for liver scarring due to fatty liver disease (2024)